Canagliflozin: a novel treatment option for type 2 diabetes
نویسندگان
چکیده
منابع مشابه
Canagliflozin: a novel treatment option for type 2 diabetes
Type 2 diabetes continues to be a challenging disease to manage. The addition of new agents with a positive risk-benefit ratio could potentially assist clinicians and patients in achieving adequate diabetes control. Canagliflozin, the first sodium-glucose cotransporter 2 inhibitor presently available on the market, offers a unique mechanism of action: it inhibits renal reabsorption of glucose, ...
متن کاملCanagliflozin (invokana), a novel oral agent for type-2 diabetes.
656 P&T® • November 2013 • Vol. 38 No. 1
متن کاملCanagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
Current guidelines for treatment of type 2 diabetes mellitus (T2DM) indicate a patient-centered approach that should go beyond glycemic control. Of the many antihyperglycemic agents available for treatment of T2DM, sodium-glucose cotransporter 2 (SGLT2) inhibitors offer the advantages of reduced glycated hemoglobin (A1C), body weight (BW), and systolic blood pressure (SBP) and are associated wi...
متن کاملExenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus.
Exenatide is the first drug in the incretin mimetic class and is indicated for treatment of type 2 diabetes mellitus. Although structurally similar to the native glucagon-like peptide, this synthetic form has a much longer duration of action. Randomized trials have shown exenatide to be efficacious in improving glycemic control when combined with either metformin or a sulfonylurea. The dose is ...
متن کاملPharmacogenomic approach in type 2 diabetes treatment
Introduction: Type 2 diabetes (T2D) is chronic health caused by the interaction between genetic and environmental factors that results in high blood glucose. The evidence-based guidelines for diabetes management are mainly based on lifestyle changes, control of risk factors, and the management of blood glucose levels. Although numerous antidiabetic agents have been developed over time, T2D trea...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Design, Development and Therapy
سال: 2013
ISSN: 1177-8881
DOI: 10.2147/dddt.s48937